• 5-Minute Check In: Evaluating the Use of Resmetirom in Patients with NASH and Liver Fibrosis

  • May 15 2024
  • Duración: 5 m
  • Podcast

5-Minute Check In: Evaluating the Use of Resmetirom in Patients with NASH and Liver Fibrosis

Escúchala gratis

Ver detalles del espectáculo

  • Resumen

  • First-of-its-kind medication shows promise for liver disease patients

    • Metabolic dysfunction-associated steatotic liver disease (MASLD), formerly known as non-alcoholic fatty liver disease (NAFLD), is estimated to affect nearly one-quarter of adults in the United States. Nonalcoholic steatohepatitis (NASH) is a form of MASLD that can cause liver fibrosis, cirrhosis, liver failure, and liver cancer. It is one of the most common reasons why patients need liver transplants.
    • The FDA recently granted accelerated approval to resmetirom, the first medication to treat nonalcoholic steatohepatitis (NASH) and liver fibrosis.
    • Prior to the FDA approval, there were no approved drugs to treat this disease

    In this 5-minute check in, we review the promising phase 3 data from a randomized trial that led to FDA approval including the results, the implications for patient care, and the potential to transform the landscape of NASH management

    Guest: Dr. Justin Reynolds, Associate Professor, Creighton University School of Medicine, Gastroenterologist and Transplant Hepatologist, St Joseph's Hospital and Medical Center Transplant Center in Phoenix, Arizona.

    Study: https://www.nejm.org/doi/10.1056/NEJMoa2309000
    Más Menos
activate_Holiday_promo_in_buybox_DT_T2
Más Menos

Lo que los oyentes dicen sobre 5-Minute Check In: Evaluating the Use of Resmetirom in Patients with NASH and Liver Fibrosis

Calificaciones medias de los clientes

Reseñas - Selecciona las pestañas a continuación para cambiar el origen de las reseñas.

Reseñas de Audible.com

Opiniones de Amazon
No hay comentarios disponibles